![Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial - The Lancet Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/ba408109-74f8-4498-958a-dfd68387092f/gr1.gif)
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial - The Lancet
PUMA: A Unified Framework for Penalized Multiple Regression Analysis of GWAS Data | PLOS Computational Biology
![Synthesis of New Bioactive Indolyl-1,2,4-Triazole Hybrids As Dual Inhibitors for EGFR/PARP-1 Targeting Breast and Liver Cancer Cells | ACS Omega Synthesis of New Bioactive Indolyl-1,2,4-Triazole Hybrids As Dual Inhibitors for EGFR/PARP-1 Targeting Breast and Liver Cancer Cells | ACS Omega](https://pubs.acs.org/cms/10.1021/acsomega.2c06531/asset/images/medium/ao2c06531_0012.gif)